TSI Group is proud to announce that 2023 Nutrition Research Project of the Year Award from NutraIngredients-USA goes to the NIH-funded Hobamine study.

NEW Study Shows 2-HOBA Supplementation has a Promising Impact on Immune Health.

TSI Group is proud to announce positive results from a recent NIH-funded study on the impact of 2-hydroxybenzylamine (2-HOBA), TSI’s branded ingredient Hobamine, on inflammatory biomarkers.

Balance is Essential to a Proactive Approach to Immune Health

The NIH-funded study, published in the journal Inflammation, found that supplementing with 2-HOBA improved as many as 15 inflammatory biomarkers in healthy individuals, thereby promoting a healthy balance of the immune system.

“Normally, inflammation is self-limiting, and its resolution is the first step in the repair and regeneration of injured tissues. Failure of inflammation resolution can lead to the progression of several diseases,” says John A. Rathmacher, Ph.D., Director of Clinical Research and Laboratory Services at MTI BioTech, Inc. That’s why a balanced immune system is incredibly important.

Opportunities for Immune Formulations

“These results enable us to enter a new space in immune health and will guide us in future research,” comments TSI Group Vice President of Business Development Shawn Baier, M.S., M.B.A. “More significantly, this opens opportunities for formulators and developers to add Hobamine to their immune formulas because it clearly enables healthy individuals to be more proactive about maintaining their immune readiness.”

This concept of immune readiness is perhaps what Baier finds most exciting. “If you don’t have 2-HOBA present, and your body creates these highly-reactive, proinflammatory compounds, it could begin an unhealthy snowball effect. Having 2-HOBA on board means it’s ready and there when it’s needed. It supports your immune system’s ability to stay in balance, even when you are exposed to oxidative stressors.”

Read the study or correlating articles below.